This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: M35.2 | Special Copayment Reduction: V139 (rare disease Special Copayment Reduction) |
| B. Synonyms | Behçet syndrome, oculo-oral-genital triad, Silk Road disease |
| C. Adult onset | Likelihood of first presentation in adulthood high — typically first diagnosed in the 20s–40s; pediatric onset is rare, and first onset after age 50 has also been reported. First diagnosis in adulthood is the standard presentation pattern of the disease. |
| 1. History | In 1937, Turkish dermatologist Hulusi Behçet described the triad of oral and genital ulcers and uveitis as an independent disease. Later reclassified as a systemic vasculitis. |
| 2. Causes | Immune-mediated vasculitis of unknown cause. Strong association with the HLA-B*51 allele. Combined involvement of infection (especially oral streptococci), environmental factors, and immune abnormalities is presumed. |
| 3. Genetics | HLA-B*51 positive in 50–80% of patients worldwide. GWAS identified polymorphisms in immune regulatory genes such as IL-10, IL-23R/IL-12RB2, and STAT4. |
| 4. General epidemiology | High prevalence in countries along the Silk Road (Turkey, Iran, Japan, Korea, etc.). Turkey 80–300 per 100,000, Japan about 13, Korea about 3–5. A severe course is common in men. |
| 5. Pathophysiology | Neutrophil hyperactivation, CD4+ T cell (Th1/Th17)–skewed responses, and endothelial cell damage cause systemic vasculitis. Both small and large vessels can be involved. |
| 6. Symptoms | Recurrent oral aphthous ulcers (almost 100%), genital ulcers, ocular involvement (uveitis, retinal vasculitis), skin lesions (erythema nodosum, pseudofolliculitis), arthritis, nervous system involvement, vascular involvement. |
| 7. Signs | Periodic recurrence of oral and genital ulcers, decreased vision due to uveitis, deep vein thrombosis of the limbs, skin hyperreactivity (positive pathergy test), joint swelling. |
| 8. Screening | No specific screening test. Clinical diagnosis is the rule. Pathergy test, HLA-B51 typing, and findings such as anemia, ESR, CRP, and neutrophilia are used for reference. |
| 9. Diagnosis | Apply the International Study Group for Behçet's Disease (ISGBD) 1990 criteria or the revised 2014 International Criteria (ISC). Recurrent oral ulcers required + 2 of: genital ulcers, ocular lesions, skin lesions, pathergy test. |
| 10. Treatment | Topical steroids (oral and genital ulcers), colchicine (skin and mucosa), azathioprine (eye, gut, vessels), TNF-α inhibitors (infliximab, adalimumab), apremilast (mucosa). |
| 11. Prognosis | Risk of blindness with recurrent ocular involvement. Neuro-Behçet and large-vessel Behçet can be fatal. Long-term remission possible with appropriate treatment. Severe course in men and young adults. |
| 12. Prevention | Early diagnosis and continuous treatment. Avoidance of relapse triggers (infection, stress, trauma). Regular ophthalmologic follow-up. Monitoring for vascular complications. |
| 13. References | Hatemi G et al. 2018 EULAR recommendations for Behçet syndrome … and 9 other references |
The formal history of Behçet disease began in 1937 when Hulusi Behçet (1889–1948), a dermatologist at Istanbul University in Turkey, described the combination of three symptoms—oral aphthous ulcers, genital ulcers, and uveitis—as an independent disease entity. In 1937 he reported this triad of symptoms in the German dermatology journal Dermatologische Wochenschrift, and the disease came to bear his name.
However, clinical records of this disease go back much further. The ancient Greek physician Hippocrates (c. 460–370 BC), while traveling in Asia Minor (present-day Turkey), described a disease accompanied by oral ulcers, genital ulcers, and ocular involvement, which is now recognized as an early record of Behçet disease. The medieval Islamic physician Ibn Sina (Avicenna, 980–1037) also described a similar clinical syndrome.
From the 20th century onward, the systemic involvement of Behçet disease gradually began to be elucidated. In 1946, the German ophthalmologist Adams-Ray emphasized the importance of ocular involvement, Odones reported nervous system involvement in 1956, and vascular involvement was reported in the 1960s. In 1974, the world's first international symposium on Behçet disease was held in Tokyo, Japan, marking the start of systematic international research.
The establishment of diagnostic criteria is also an important historical milestone. In 1990, the International Study Group for Behçet's Disease (ISGBD) published classification criteria with recurrent oral aphthous ulcers as a required item. These criteria became the standard for clinical research for decades, but because of the limitation that they could miss some patients without ocular involvement or with predominant nervous system involvement, a new score-based standard was proposed in 2014 by the International Study Group for Behçet's Disease (ISC, International Criteria for Behçet's Disease). Under these criteria, the points for oral ulcers, genital ulcers, ocular lesions, skin lesions, nervous system involvement, vascular involvement, and the pathergy test are summed, and a total of 4 points or more is classified as Behçet disease.
In Korea, case reports of Behçet disease began in the 1960s, and multicenter cohort studies led by the Korean College of Rheumatology and the Korean Dermatological Association have elucidated the domestic epidemiology and clinical characteristics. Korea is classified as an endemic area of 'Silk Road disease', and according to Health Insurance Review & Assessment Service (HIRA) data, the domestic prevalence is estimated at 3–5 per 100,000. In 2009, Behçet disease was designated as eligible for rare disease Special Copayment Reduction, reducing patients' medical cost burden, and this led to improvements in the number of registered patients in Korea and in systematic treatment.
There have also been important advances in treatment. In the 1970s, colchicine was introduced for managing skin and mucosal symptoms, and from the 1980s onward, immunosuppressive treatment centered on azathioprine, cyclosporine, and steroids was systematized. In the 2000s, clinical studies demonstrated that TNF-α inhibitors (infliximab, adalimumab) are effective for ocular, vascular, intestinal, and neuro-Behçet refractory to conventional treatment. In 2016, apremilast (a PDE-4 inhibitor) received US FDA approval for recurrent oral ulcers, adding a new targeted treatment option.
The cause of Behçet disease has not yet been fully elucidated, but it is currently understood that in individuals with a genetic predisposition, environmental stimuli (infection, trauma, other factors) trigger an abnormal immune response, resulting in systemic vasculitis. Rather than a single cause, a complex interaction of genetics, environment, and immunity is central to the pathogenesis.
Genetic factors: the strongest genetic risk factor is the HLA-B*51 allele, which is positive in about 50–80% of patients with Behçet disease worldwide. The risk of developing Behçet disease (relative risk) in HLA-B*51–positive individuals is 5–6 times higher than in the general population. HLA-B*51 occurs at particularly high frequency in Middle Eastern and East Asian populations, which partly explains the high prevalence in Silk Road regions. However, HLA-B*51–negative patients also account for 20–50% of the total, so this gene alone cannot explain disease onset.
Genome-wide association studies (GWAS) have confirmed that, in addition to HLA-B*51, polymorphisms in genes involved in immune regulation and antigen presentation, such as IL-10 (interleukin-10 gene), IL-23R/IL-12RB2, STAT4, KLRC4, and ERAP1 (endoplasmic reticulum aminopeptidase 1), are associated with susceptibility to Behçet disease. In particular, ERAP1 is involved in processing peptides to be presented on HLA molecules and is presumed to contribute to pathogenesis through its interaction with HLA-B*51.
Infectious factors: hypersensitivity to the oral commensal Streptococcus sanguinis (oral streptococcus) attracted attention from early on. Experimental results have been reported showing high serum antibody titers to streptococcal antigens in patients with Behçet disease and increased skin hypersensitivity reactions upon inoculation with oral streptococcal antigens. Associations have also been raised with antibodies to Saccharomyces cerevisiae (ASCA), herpesviruses (HSV), Helicobacter pylori, and others, but it has not been established that any single microorganism is a direct cause.
Environmental factors: physical trauma (such as oral mucosal injury) is clinically confirmed as a trigger of ulcers. The pathergy test—development of a papule or pustule of 2 mm or more 48–72 hours after pricking the skin with a needle—has a high positivity rate in patients with Behçet disease, reflecting a neutrophil hyperactivation response to physical stimuli. The pathergy positivity rate shows regional differences, being high in the Middle East and East Asia and low in the West.
Overall, the cause of Behçet disease is understood to involve the combined action of abnormal antigen presentation related to HLA-B*51, dysregulation of the IL-10 and IL-23 pathways, immune activation by infectious agents such as oral streptococci, and the triad of abnormal activation of neutrophils, T cells, and endothelial cells.
The genetic basis of Behçet disease is typified by its strong association with the MHC (major histocompatibility complex) region, particularly the HLA-B*51 allele. HLA-B51 is a specific allele at the HLA-B locus (chromosome 6p21.3); differences in its amino acid sequence change the repertoire of peptides it presents, and it has been suggested that this may induce the immune response characteristic of Behçet disease. However, the exact mechanism by which HLA-B*51 contributes to the development of Behçet disease has not yet been fully clarified.
The main associated genes identified in GWAS studies can be summarized as follows. IL-10 gene polymorphisms (especially rs1518111) reduce interleukin-10 expression and weaken anti-inflammatory function, predisposing to chronic recurrent inflammation. IL-23R/IL-12RB2 are receptors that regulate the Th17 pathway, and abnormal activation of this pathway leads to IL-17 oversecretion and neutrophil hyperactivation. STAT4 is a key transcription factor in IL-12 and IL-23 signaling that promotes Th1 differentiation, and STAT4 polymorphisms are associated with several autoimmune diseases including Behçet disease. ERAP1 is an enzyme that processes peptides in the endoplasmic reticulum for presentation on MHC I molecules and appears to contribute to Behçet disease susceptibility through its interaction with HLA-B*51.
The familial occurrence rate of Behçet disease is not high, at about 2–3%, but there are reports that the morbidity rate in first-degree relatives is 11–52 times that of the general population. Identical twin studies also do not show 100% concordance (concordance about 36%), suggesting that genetic factors are necessary but not sufficient and that environmental factors also play a role. Associations between presentation patterns (oral-predominant, ocular-predominant, vascular-predominant, etc.) and genotype are also being studied, but no genetic marker that reliably predicts a specific phenotype has been established to date.
The clinical utility of genetic testing is limited. HLA-B51 typing is used in some cases as a diagnostic aid, but a diagnosis cannot be made or excluded on the basis of positivity alone. Therefore, the diagnosis of Behçet disease relies on clinical symptoms and international criteria, and genetic testing is used as supplementary information when the diagnosis is unclear. In the future, GWAS, single-cell transcriptome analysis, and epigenome research are expected to further clarify the molecular pathways of Behçet disease.
Behçet disease occurs worldwide, but its prevalence is markedly high in the 'Silk Road' region extending from the eastern Mediterranean coast through the Middle East and Central Asia to East Asia, giving it the nickname 'Silk Road disease'. This regional variation broadly matches the distribution of the HLA-B*51 allele.
Prevalence by country (per 100,000 population) is highest in Turkey at 80–300, with Iran 80, Saudi Arabia 20, Israel 15–30, Japan 13, Korea about 3–8, and China 10–14 reported. In Western Europe and North America, prevalence is very low, at 1 per 100,000 or less. Studies of migrant populations report that Turkish immigrants maintain a high prevalence even in Germany, whereas prevalence decreases among descendants of Japanese immigrants, suggesting that both genetics and environment are important.
The age at onset is typically the 20s–40s; pediatric onset accounts for about 3–10% of the total, and first onset after age 50 is rare. Sex differences vary by region: in Turkey, Japan, and Korea the male-to-female ratio is similar or slightly male-predominant, while some Western studies report female predominance. In terms of clinical severity, serious complications of ocular, nervous system, and vascular involvement are more common in men.
According to Korean Health Insurance Review & Assessment Service (HIRA) data, the annual number of patients treated for Behçet disease is estimated at about 15,000–20,000, and the number of patients registered under rare disease Special Copayment Reduction (V139) is smaller. According to Korean studies, the clinical features of Korean patients with Behçet disease appear in the order of oral ulcers (almost 100%), genital ulcers (about 60–70%), skin lesions (about 60%), ocular involvement (about 30–40%), and arthritis (about 40–50%), with somewhat less ocular involvement and relatively more intestinal involvement than in Western countries.
The pathogenesis of Behçet disease is explained by combined abnormalities of innate and adaptive immunity. The core mechanisms can be summarized as neutrophil hyperactivation, skewed T cell responses (Th1/Th17 predominance), and endothelial cell damage and vasculitis.
Neutrophil hyperactivation: peripheral blood neutrophils of patients with Behçet disease show increased expression of activation surface molecules (CD64, CD18) and enhanced oxidative burst, degranulation, and neutrophil extracellular trap (NET) formation. This neutrophil hyperactivation directly damages the vascular endothelium and acts as a core mechanism of tissue destruction and ulcer formation. A positive reaction on the pathergy test—skin neutrophil infiltration in response to microtrauma—directly reflects this mechanism.
Th1/Th17 skewing: in patients with Behçet disease, proinflammatory cytokines such as IFN-γ (Th1), IL-17 (Th17), IL-12, and IL-23 are markedly elevated. Th17 cells and IL-17 in particular contribute to neutrophil recruitment, increased endothelial permeability, and mucosal destruction. In contrast, the function and number of regulatory T cells (Tregs) are relatively reduced, lowering immune self-tolerance. Reduced IL-10 expression due to IL-10 gene polymorphisms weakens anti-inflammatory mechanisms.
Vascular endothelial damage and vasculitis: Behçet disease has the character of a panvasculitis that can involve both veins and arteries. Cytokines and reactive oxygen species secreted by activated T cells and neutrophils cause dysfunction and apoptosis of vascular endothelial cells. Activation of vascular endothelial cells increases the expression of adhesion molecules such as VCAM-1 and ICAM-1 and promotes leukocyte infiltration. Both venous involvement (thrombophlebitis, deep vein thrombosis) and arterial involvement (aneurysms, pulmonary artery aneurysms) are observed.
Mechanism of neuro-Behçet: the main mechanisms are central nervous system infiltration by immune cells that have crossed the blood-brain barrier and small-vessel vasculitis. Inflammatory lesions of the brainstem, basal ganglia, and cerebral white matter are characteristic and appear as T2 hyperintense lesions on MRI. Rarely, venous sinus thrombosis causes increased intracranial pressure and headache.
Behçet disease is a systemic vasculitis that involves various organs, and the type and severity of symptoms differ greatly from patient to patient. A course of repeated relapse and remission is characteristic, and because symptoms do not appear simultaneously but may emerge sequentially over several years, diagnosis is often delayed.
Oral aphthous ulcers: occur in almost all patients (95–100%) and are often the first symptom. They are single or multiple round or oval ulcers 2–10 mm in diameter with well-defined borders and severe pain. They can occur anywhere on the oral mucosa but are common on the inner cheeks, tongue, lips, and palate. Recurrence 3 or more times a year is the criterion, and some patients have ulcers almost continuously. They usually heal without scarring within 1–2 weeks, but large ulcers (major aphthae, >10 mm) persist for several weeks and may leave scars.
Genital ulcers: aphthous ulcers similar to oral ulcers occur on the scrotum in men and on the vulva and vagina in women. They are very painful and often leave scars, so the presence of scars itself is useful for diagnosis. They are less frequent than oral ulcers, occurring in about 60–90% of all patients.
Ocular symptoms: uveitis is the most common ocular lesion, presenting as anterior uveitis (iritis, cyclitis) and posterior uveitis (retinal vasculitis, vitritis). Ocular involvement occurs in 30–70% of all patients, is especially common in young men, and can lead to vision loss if untreated. Symptoms include red eye, photophobia, decreased vision, and floaters.
Skin lesions: erythema nodosum, pseudofolliculitis, acneiform lesions, and superficial thrombophlebitis appear. Erythema nodosum consists of tender red nodules mainly on the pretibial areas of the lower legs, and pseudofolliculitis differs from ordinary folliculitis in that it also occurs at sites not centered on hair follicles.
Joint symptoms: non-erosive, non-deforming arthritis or arthralgia appears in about 40–50% of all patients. It mainly involves single or multiple large joints such as the knees, ankles, wrists, and elbows, and unlike ankylosing spondylitis, the spinal joints are rarely involved. Joint destruction is extremely rare.
Vascular and other organ symptoms: vascular involvement such as deep vein thrombosis, pulmonary artery aneurysms, superior and inferior vena cava thrombosis, and Budd-Chiari syndrome occurs in about 10–40% of the total and can be life-threatening. Intestinal Behçet (ileocecal ulcers, multiple colonic ulcers) causes abdominal pain, rectal bleeding, and diarrhea. Neuro-Behçet presents as brainstem involvement, cerebral venous sinus thrombosis, or meningoencephalitis, causing headache, paralysis, and cognitive impairment.
The physical signs of Behçet disease vary greatly depending on the organs involved and disease activity. Because there is no specific single test finding, a combination of clinical signs is central to diagnosis.
Features of oral and genital ulcers: oral mucosal aphthous ulcers are well-demarcated round to oval ulcers covered by a white or yellow pseudomembrane and surrounded by erythema. Genital ulcers are strongly suggestive of the diagnosis, particularly when scarred healing is observed on the scrotum.
Pathergy test: the skin of the inner forearm is pricked with a 20-gauge needle, and the result is judged positive if a papule or pustule of 2 mm or more forms at the prick site 24–48 hours later. The positivity rate is high in Middle Eastern and East Asian patients (about 40–70%) and low in Western patients (about 5–20%), a large regional difference. This test is a useful clinical adjunct that directly demonstrates skin neutrophil hyperreactivity.
Ocular findings: on slit-lamp examination, anterior chamber cells (flare and cell) and keratic precipitates are signs of anterior uveitis. On fundus examination, exudates around the retinal vessels, retinal hemorrhage, and papilledema suggest posterior uveitis. Vascular leakage and retinal vasculitis on fluorescein fundus angiography (FFA) are characteristic. Elevated intraocular pressure, posterior synechiae, hypotony, and complicated cataract appear as long-term complications.
Skin signs: erythema nodosum consists of subcutaneous nodules that are tender on palpation and usually resolve within 2–3 weeks. Pseudofolliculitis also occurs at sites without hair follicles and has an erythematous rim around the pustule.
Vascular and neurological signs: with deep vein thrombosis, leg swelling, pain, erythema, and warmth appear. Hemoptysis from rupture of a pulmonary artery aneurysm is a serious life-threatening sign. In neuro-Behçet, brainstem dysfunction (abnormal eye movements, dysarthria, dysphagia) and pyramidal signs (hemiplegia, hemisensory disturbance) may appear.
Laboratory findings: in the acute phase, elevated ESR and CRP, increased white blood cells (especially neutrophils), and increased platelet reactivity appear. Anemia (anemia of chronic disease) is also observed. HLA-B51 typing (positive in 50–80%), proteinuria and hematuria (with renal involvement), and cerebrospinal fluid analysis (mononuclear pleocytosis and elevated IgG in neuro-Behçet) are used as diagnostic aids. To date, no autoantibodies specific to Behçet disease (ANA, ANCA, etc.) have been established.
Because Behçet disease has no specific serum biomarkers or imaging findings, there is no standard screening test for the general population. Diagnosis is in principle clinical, relying on a combination of clinical symptoms. However, systematic clinical evaluation in at-risk groups and strategic use of ancillary tests help with early diagnosis.
Clinical screening indicators: in patients in their 20s–40s, recurrent (3 or more times a year) oral aphthous ulcers are the most important screening indicator. In particular, when oral ulcers are accompanied by one or more of genital ulcers, red eye (uveitis), or skin lesions (erythema nodosum, pseudofolliculitis), the possibility of Behçet disease should be actively considered. When these symptoms occur in patients from Silk Road regions (Turkey, Iran, Japan, Korea, the Middle East, etc.), the diagnostic probability is higher.
Pathergy test: in patients with oral ulcers and other symptoms, the flexor skin of the forearm is pricked with a 20-gauge needle and checked for papule or pustule formation 48 hours later. High specificity in Middle Eastern and East Asian patients (about 90%).
HLA-B51 typing: used as supplementary diagnostic information in patients suspected of having Behçet disease. A positive result increases the likelihood of the diagnosis but is not an independent diagnostic tool, and a negative result is not an exclusion criterion.
Inflammatory markers: ESR, CRP, complete blood count, liver function tests, and urinalysis are useful for assessing the degree of inflammation and organ involvement. They are also used to monitor activity.
Ophthalmologic examination: even without ocular symptoms, slit-lamp and fundus examinations are recommended after Behçet disease is confirmed, to detect asymptomatic uveitis early. If ocular involvement is present, retinal vasculitis and macular degeneration are evaluated with fluorescein fundus angiography (FFA) or OCT (optical coherence tomography).
Brain and vascular imaging: if neurological symptoms are present, brain lesions and venous sinus thrombosis are evaluated with brain MRI (T2, FLAIR, DWI) and MR angiography. If vascular symptoms are present, thrombi and aneurysms are identified with CT angiography or Doppler ultrasound.
The diagnosis of Behçet disease is based on clinical criteria, and the absence of specific serological or histological tests is an important feature distinguishing it from other autoimmune diseases. The most widely used criteria in current clinical practice are the 1990 International Study Group for Behçet's Disease (ISGBD) criteria and the 2014 International Criteria (ISC).
1990 ISGBD criteria: recurrent oral aphthous ulcers (3 or more times a year) are a required item, and the diagnosis is made when 2 or more of the following 4 are met: ① recurrent genital ulcers, ② ocular lesions (anterior/posterior uveitis or retinal vasculitis), ③ skin lesions (erythema nodosum, pseudofolliculitis, acneiform lesions), ④ positive pathergy test. These criteria have a sensitivity of about 78–91%, but have the limitation that they may miss some patients without oral ulcers early on or with atypical presentations.
2014 International Criteria (ISC): a score-based classification system in which Behçet disease is classified when the sum of points for oral ulcers (2 points), genital ulcers (2 points), ocular lesions (2 points), skin lesions (1 point), neurological symptoms (1 point), vascular involvement (1 point), and positive pathergy test (1 point) is 4 or more. Because these criteria do not make oral ulcers a required item, they can include atypical patients, and sensitivity is slightly improved. The sensitivity of the ISC is reported at about 93–96% and specificity at about 90–92%.
Differential diagnosis: Behçet disease needs to be differentiated from a variety of diseases. With oral ulcers alone, recurrent aphthous stomatitis and cyclic neutropenia are differentiated. With intestinal symptoms, differentiation from Crohn's disease is particularly important; ulcers in intestinal Behçet appear as single or a few deep ulcers in the ileocecal region, whereas Crohn's disease is characterized by continuous inflammation and granulomas. With ocular involvement, sarcoidosis and HLA-B27–associated uveitis are differentiated. With nervous system involvement, multiple sclerosis and CNS vasculitis must be excluded.
Biopsy: not essential for the diagnosis of Behçet disease, but nonspecific perivascular neutrophil infiltration, mononuclear cell infiltration, and small-vessel vasculitis on biopsy of skin lesions, intestinal ulcers, and vascular lesions are used as supplementary information. There are no specific granulomas on biopsy of the ulcer base.
Applying the classification criteria in practice: clinically, the ISGBD 1990 or ISC 2014 criteria are used, but the actual diagnosis is often made through multidisciplinary collaboration among rheumatology, ophthalmology, dermatology, neurology, gastroenterology, vascular surgery, and others. Because symptoms may appear sequentially over several years, regular follow-up is essential even if the criteria are not met initially.
Treatment of Behçet disease is individualized according to the organs involved, severity, and patient characteristics; there is no cure to date, so the goals are symptom control and prevention of organ damage. The evidence for treatment is based mainly on observational studies and small randomized controlled trials, and the 2018 EULAR recommendations are used as the international standard.
Topical treatment (mucosal lesions): for mild oral and genital ulcers, topical steroids (triamcinolone dental ointment, dexamethasone mouthwash), topical anesthetics, and topical tetracycline suspension are effective for pain relief and promoting healing. Topical antibiotic ointment (chlorhexidine) is used to prevent secondary infection.
Colchicine: effective for erythema nodosum, arthritis, and genital ulcers, and partly helpful in preventing oral ulcers. It acts by inhibiting neutrophil function and can be used long term at a dose of 0.5–1.5 mg/day. It is the most widely used long-term maintenance treatment for Behçet disease.
Apremilast: a PDE-4 (phosphodiesterase-4) inhibitor that increases cAMP and suppresses proinflammatory cytokines such as TNF-α, IL-17, and IL-23. It received US FDA and European EMA approval for recurrent oral ulcers in 2021. 30 mg orally twice daily. Nausea, headache, and diarrhea are common side effects but are usually mild and improve spontaneously.
Azathioprine: used in combination with corticosteroids for major organ involvement such as ocular involvement, intestinal involvement, neuro-Behçet, and vascular involvement. Used at a dose of 2.5 mg/kg/day for maintenance of remission. The risk of myelotoxicity is assessed in advance by TPMT genotyping. In ocular Behçet, combination with cyclosporine A is also used.
Biologics — TNF-α inhibitors: infliximab or adalimumab is used for severe ocular involvement, intestinal involvement, vascular involvement, and neuro-Behçet refractory to conventional immunosuppressants. Infliximab acts rapidly in acute severe uveitis and large-vessel involvement, and under Korean National Health Insurance coverage criteria it can be applied to Behçet uveitis. Adalimumab is an alternative in patients who are refractory to or have side effects with infliximab.
Corticosteroids: systemic steroids are used for acute severe symptoms (acute uveitis, neuro-Behçet, acute phase of vascular involvement), but long-term use alone is not recommended because of side effects. The principle is short-term high doses in the acute phase → transition to maintenance immunosuppressants.
Treatment of vascular and thrombotic Behçet: for venous thrombosis, immunosuppression (steroids + azathioprine or TNF-α inhibitors) takes priority over anticoagulation (heparin, warfarin, NOACs). This is because the main cause of the thrombosis is inflammation of the vessel wall. Aneurysms require surgical treatment combined with immunosuppression, and pulmonary artery aneurysms are life-threatening and require immediate intervention.
Treatment of neuro-Behçet: for acute neurological involvement, high-dose intravenous steroids (methylprednisolone 1 g/day for 3–5 days) are used, followed by maintenance with azathioprine or mycophenolate mofetil. TNF-α inhibitors are used for relapsing or refractory neuro-Behçet, but caution is needed because, paradoxically, they can rarely induce neurological involvement.
The prognosis of Behçet disease varies greatly with the organs involved and severity. Patients with only mucocutaneous symptoms have a relatively good course, but serious morbidity and mortality are reported in patients with ocular, neurological, or vascular involvement.
Ocular prognosis: in untreated ocular Behçet, the rate of blindness within 5–10 years of diagnosis reached 25–30%, but this has improved markedly with active use of azathioprine and TNF-α inhibitors. Early diagnosis and aggressive treatment are key to preserving vision. Recurrent attacks of uveitis are most dangerous, particularly in young male patients. Regular ophthalmologic follow-up and maintenance immunosuppression are key to long-term preservation of vision.
Neurological and vascular prognosis: neuro-Behçet accounts for a major share of all causes of death, and the prognosis is particularly poor in patients with brainstem involvement and a chronic progressive course. Recurrent neurological involvement accumulates cognitive decline and disability. Large-vessel involvement (pulmonary artery aneurysms, aortic aneurysms) is fatal upon acute rupture, and massive hemoptysis from rupture of a pulmonary artery aneurysm is an immediate cause of death. Deep vein thrombosis is likely to recur, but recurrence can be reduced with appropriate immunosuppressive treatment.
Long-term course: typically, disease activity is high early after onset and tends to gradually subside with age. More than 10 years after onset, the frequency of oral ulcer recurrence decreases in some patients. However, ocular damage, neurological deficits, and vascular sequelae that have already occurred are difficult to recover from. Quality of life is significantly reduced by ocular involvement, fatigue, pain, intestinal symptoms, and the like.
Mortality: in Western cohorts, excess mortality due to Behçet disease is relatively low compared with the general population, but in Middle Eastern and East Asian cohorts, mortality due to vascular and neurological involvement is relatively high. The main causes of death are hemorrhage from rupture of pulmonary artery aneurysms, functional decline and complications due to neuro-Behçet, and infections due to immunosuppressive treatment.
Follow-up: patients with Behçet disease should be evaluated regularly by a multidisciplinary team centered on rheumatology and including ophthalmology, neurology, gastroenterology, vascular surgery, and others. Ophthalmologic examination is performed every 6–12 months even if asymptomatic, and brain MRI and vascular imaging are used actively in patients with neurological or vascular symptoms. Registration of patients with Behçet disease and standardized collection of follow-up data are being carried out in several countries, including Korea.
Primary prevention of Behçet disease (preventing onset itself) is currently impossible. Because the cause has not been fully elucidated and the disease does not develop in every individual with a genetic predisposition, current prevention strategies focus on early diagnosis, relapse prevention, and prevention of complications.
Avoiding relapse triggers: oral mucosal trauma (hard foods, irregular dental alignment, poor oral hygiene) can promote ulcer recurrence, so oral hygiene care and regular dental checkups are recommended. Psychological stress has been reported as a relapse trigger, so stress management education is helpful. Hormonal changes (menstruation, pregnancy) can also affect relapses, so additional monitoring is needed in female patients. Physical trauma (surgery, invasive procedures) can promote local inflammation, as in the pathergy phenomenon, so it is important to minimize disease activity before procedures.
Long-term colchicine maintenance therapy: the most common method for preventing relapses of Behçet disease is long-term colchicine administration. It is particularly effective in reducing the frequency of relapses of mucocutaneous symptoms and arthritis, and is used as a first-line long-term management drug in patients without major organ involvement.
Early diagnosis and multidisciplinary follow-up: in patients with recurrent oral ulcers, the presence of genital ulcers, ocular symptoms, and skin lesions is systematically evaluated to minimize diagnostic delay. In particular, because retinal damage can progress even without symptoms in ocular involvement, regular ophthalmologic examinations are essential.
Infection prevention: in patients receiving immunosuppressive treatment, vaccinations (influenza, pneumococcal vaccines) are kept up to date and tuberculosis screening (LTBI testing) is performed to prevent opportunistic infections. Before using biologics, testing for hepatitis B carrier status, latent tuberculosis, and HIV is essential.
Pregnancy planning and management: pregnancy is generally possible for women with Behçet disease, but drug adjustments that take into account changes in disease activity during pregnancy and fetal safety are needed. MTX, MMF, and cyclophosphamide are contraindicated during pregnancy, so drugs must be switched before planning a pregnancy. Preconception preparation and monitoring during pregnancy are carried out in collaboration between obstetrics and gynecology and rheumatology.